This transaction will expand BioIVT’s biospecimen collection network by approximately 150 sites in the US, UK, and Europe and broaden its offerings for drug and diagnostic developers.
Westbury, NY – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced the acquisition of Valley Biomedical Products & Services, Inc. located in Winchester, VA.
Rheoscan (model: Rheoscan-And300, Rheoscan-D300) system is an in vitro diagnostic device that tests the erythrocyte deformability, aggregation, and critical shear stress used as a POC device.
ALCEDIAG, one of 3 finalists for the “Disruptive Technology Award” at the annual AACC meeting 2020, will be holding a press conference to announce a game-changing technology and diagnostic tool for precision medicine in psychiatry: EDIT-BTM, the very first blood test for a high-performance differential diagnosis of unipolar depression and bipolar disorder.
AnteoTech marks its entry into the Assay Development market through the design of a high sensitivity COVID-19 Antigen Rapid Test. The test uses an AnteoBind™ activated Europium particle to enable the detection of low viral loads. AnteoTech is pleased to announce the expansion of its business to include Assay Development in addition to its existing Raw Material Supply business.
Join us for an overview of MedSchenker’s product lines, including our Smart Transport Medium (STM™) and CavSwabs, among other innovations we introduced to the market this past year.
GenScript USA Inc., the world’s leading research reagent provider, announced today that Brazil's National Health Surveillance Agency (ANVISA) (Agência Nacional de Vigilância Sanitária) has authorized the use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit for detecting neutralizing antibodies. The cPass test is the first and only ANVISA authorized test for detecting neutralizing antibodies to SARS-CoV-2. Neutralizing antibodies specifically block the ability of a virus to infect a cell and are well-recognized to confer immunity.
At the 2020 AACC Annual Scientific Meeting & Clinical Lab Expo, a series of late-breaking sessions will delve into the newest research on the rapidly evolving COVID-19 pandemic. Highlights of these sessions include a talk that will provide expert insight into the many coronavirus vaccines currently in development, as well as an expert presentation on coronavirus immunity and antibody testing.
Area9 Lyceum will participate in the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting, to be held December 13-17, 2020, joining an online community to share the latest developments in scientific education. Participants will have the opportunity to experience the world’s leading adaptive learning program for laboratory medicine, based on Area9’s adaptive platform.
Sysmex America, Inc., a leading diagnostic solutions company offering hematology, urinalysis, information systems and flow cytometry testing technology for optimal clinical laboratory performance, will be exhibiting virtually at the 72nd AACC Annual Scientific Meeting & Clinical Lab Expo, December 14 – 17.
Aim Lab Automation Technologies pre-analytical and post analytical COVID-19 PathFinder benchtop automation solutions can help overcome many of these COVID-19 related challenges and reduce the risk of biohazards exposure to staff.
AnteoTech marks its entry into the Assay Development market through the design of a high sensitivity COVID-19 Antigen Rapid Test. The test uses an AnteoBind™ activated Europium particle to enable the detection of low viral loads. AnteoTech is pleased to announce the expansion of its business to include Assay Development in addition to its existing Raw Material Supply business.
AACC is pleased to announce the recipients of the AACC 2020 Top Corporate Supporter Awards. This year, AACC recognizes 45 different companies and organizations that generously support the association through sponsorships, advertising, and exhibiting. These significant contributions make it possible for AACC to improve patient care by fostering research, innovation, and professional excellence in the field of laboratory medicine.
Artificial intelligence (AI) has the potential to revolutionize healthcare, but integrating AI-based techniques into routine medical practice has proven to be a significant challenge. A plenary session at the virtual 2020 AACC Annual Scientific Meeting & Clinical Lab Expo will explore how one clinical lab overcame this challenge to implement a machine learning-based test, while a second session will take a big picture look at what machine learning is and how it could transform medicine.
During the all-virtual 2020 AACC Annual Scientific Meeting & Clinical Lab Expo, leading scientific experts will dive into the groundbreaking advances that are the future of cancer care. One plenary session will focus on the cutting-edge treatment known as T cell therapy, while another will showcase recent discoveries about tumor metabolism that could lead to new, more effective cancer drugs.
The opioid epidemic has only gotten worse since the advent of COVID-19, with some areas in the U.S. reporting a 50% increase in drug overdoses due to the pandemic. With no end in sight to this public health crisis, scientific sessions during the virtual 2020 AACC Annual Scientific Meeting & Clinical Lab Expo will highlight the integral role of clinical laboratories in efforts to manage it, as well as the latest drug tests needed to do so.
A new study shows that a first-of-its-kind rapid test could identify which COVID-19 patients are responding to drug treatments and which patients are still deteriorating and need higher doses of medication. Findings on this method and on a second test that could predict COVID-19 severity were presented today at the virtual 2020 AACC Annual Scientific Meeting & Clinical Lab Expo.
In the wake of the novel coronavirus pandemic, the need for reliable, accurate, and accessible laboratory testing is more evident than ever before. At the 2020 AACC Annual Scientific Meeting & Clinical Lab Expo, laboratory medicine experts will present the cutting-edge research and technology that is revolutionizing clinical testing and patient care for COVID-19 and across the spectrum of healthcare.
The Tube Decapper is an OEM Module designed for easy integration into any analyser or automation system to automate the decapping of specimen collection tubes.
Diamond Technologies is proud to announce the release of the new DE02 an industrial embedded barcode scan module for laboratory and medical devices as well as kiosks and automated machines.
Diamond Technologies is proud to announce the release of the new DE05 Industrial embedded barcode scan module for laboratory and medical devices as well as kiosks and automated machines.
The plasma volume status of a patient is one of the top priorities in evaluating and treating many different conditions including, shock, sepsis, congestive heart failure, acute or chronic kidney disease, chronic pulmonary disease, as well as general postoperative care.
New glucose reference correlation analyzer replaces "gold standard" YSI 2300
The IFCC announces the IFCC Global Conference on COVID-19 that will take place virtually on February 15-17, 2021. The theme of this conference will be the “Critical Role of Clinical Laboratories in the COVID-19 Pandemic".
The IFCC Information Guide on COVID-19, initially published on 23 March 2020, is continuously updated. A Summary of the Guide in Spanish and Czech is also available.
Announcement of the 3 top winners, 9 teams of distinction, and 12 teams of achievement of the Awards programme. The 2020 submissions included hospitals, commercial laboratories, reference laboratories, clinics and rural community care.
The biennial EuroMedLab congresses bring together scientists, laboratory specialists, clinicians, and industry professionals in the field of laboratory medicine.
Worthington, the leading supplier of specialty enzymes for over 70 years, announces today the publication of an expanded, 2021-22 Enzyme and Biochemical Product Catalog. As a primary enzyme producer for biochemistry, cell biology, molecular biology, pre-clinical research and bioprocessing applications, Worthington is the “go-to” expert in enzyme technology.
Instrumentation Laboratory Receives US FDA Marketing Authorization for the First Apixaban Diagnostic Test
Baebies has been named a finalist for the 2020 American Association for Clinical Chemistry’s (AACC) Disruptive Technology Award for FINDER®, a near-patient testing platform. As a growth-stage company developing diagnostic products to provide a healthy start for children everywhere, Baebies FINDER tests for diseases from low blood volume (50 µL) with a turn-around time of approximately 15 minutes after sample introduction.
Laboratory developed tests play a vital role in getting patients accurate diagnoses and effective care, and at no time has their importance been clearer than during the current pandemic. In this briefing, AACC’s leading experts in laboratory medicine will discuss why laboratory developed tests are crucial to fighting the coronavirus, as well as the regulatory barriers that nearly prevented labs from developing and introducing these tests for the virus.
In the face of a chronic shortage of professionals who are qualified to perform clinical laboratory tests—including those for COVID-19—AACC released a position statement today calling on Congress to provide federal funding to expand clinical laboratory training programs. This will help to ensure that labs have the staffing they need to deliver timely, accurate test results, particularly during public health emergencies such as the current coronavirus pandemic.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce a new collaboration with the Centers for Disease Control and Prevention (CDC) and the CDC Foundation that aims to expand lipid testing in resource-limited countries. Improving access to this essential testing could help reduce the high worldwide mortality rate from cardiovascular disease by enabling patients to get treated for this condition earlier.
A novel study in AACC’s Clinical Chemistry journal shows that a new test for SARS-CoV-2 viral proteins known as antigens could determine which COVID-19 patients are most likely to become critically ill. This test could help improve management of COVID-19 by enabling hospitals to ensure that these patients have access to intensive care.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that Senator Roy Blunt (R-Missouri) is the recipient of AACC’s Outstanding Legislator Award for the 116th Congress. This award recognizes Sen. Blunt for his tireless efforts to improve children’s healthcare by advancing the development of pediatric reference intervals.
AACC welcomes a decision from the Department of Health and Human Services that the Food and Drug Administration does not have authority to regulate laboratory developed tests (LDTs) without formal notice-and-comment rulemaking.
A new survey of U.S. clinical laboratories conducted by AACC has found that nearly half of all responding labs still do not have the supplies they need to run COVID-19 tests. AACC presented these findings to the White House Coronavirus Task Force today in a letter that calls on the federal government to take a more active role in alleviating this problem, so that labs can increase their testing capacity in the midst of the virus’s latest surge.
Dr. Grenache addresses the growing push for COVID-19 antibody testing, bringing much-needed clarity to the question of what these tests can—and can’t—do.
AACC President-Elect Dr. David Grenache discusses what we know so far about the body’s immune response to COVID-19, and why the presence of antibodies to the novel coronavirus doesn’t yet tell us whether or not a person is immune.
Dr. Wiley gives an overview of PCR testing, which is the most common type of test for COVID-19 and the one that patients are currently most likely to encounter.
Now that lab experts are developing COVID-19 antigen tests, Dr. Wiley explains how these tests work.
Dr. Wiley sheds light on why testing capacity remains frustratingly limited, explaining that shortages of crucial supplies are a significant obstacle to widespread testing—and what the federal government can do to remedy this issue.
We at AACC would like to thank Assistant Secretary for Health Admiral Brett P. Giroir, MD, for his leadership in establishing the National Testing Implementation Forum to address the persistent challenges that the U.S. is facing with COVID-19 testing and for inviting us to participate in this initiative.
Medical experts support the ongoing protests against racist police killings and brutality, but experts do also worry these protests could increase coronavirus spread.
As supply shortages continue to hamper COVID-19 testing, AACC President Dr. Carmen Wiley explains how pooled testing could enable clinical labs to process more tests while saving the materials needed to run them.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that the impact factor of its journal, Clinical Chemistry, has risen to 7.292 in the 2019 Clarivate Analytics Journal Citation Reports. This impact factor places Clinical Chemistry in the top 4.2% of 12,838 ranked academic journals and speaks to the significant influence of the science it publishes on laboratory medicine and patient care.
In response to the Senate health committee’s white paper on preparing for future pandemics, AACC sent a letter to committee leadership detailing four key steps the government should take to ready the U.S. for the next outbreak. AACC urges the health committee to address these recommendations in future pandemic legislation, as they are crucial to preventing another public health crisis like the one COVID-19 has caused.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that Stephen R. Master, MD, PhD, FAACC, has been elected to serve on the AACC Board of Directors as president-elect starting in August 2020.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that its Board of Directors has appointed Mark J. Golden as CEO effective August 17.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce a new competition that will support cutting-edge research that could significantly improve diagnostic testing and patient care. Winners of the competition will each receive a sample set from AACC’s Universal Sample Bank, which includes blood samples from hundreds of healthy individuals that were collected to aid medical studies.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right